Clinical trial
Patient-reported Outcomes in the Treatment of Schizophrenia
NCT00230828 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00230828 |
|---|---|
| Title | Patient-reported Outcomes in the Treatment of Schizophrenia |
| Official title | Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | bifeprunox |
| Start date | May 1, 2005 |
| Primary completion | Jan 1, 2006 |
| First posted | Oct 3, 2005 |
| Last update posted | Sep 12, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: